Financial Performance - The company's operating revenue for Q1 2024 was ¥504,874,103.59, representing a year-on-year increase of 20.68%[6] - The net profit attributable to shareholders decreased by 63.76% to ¥16,757,351.46, while the net profit after deducting non-recurring gains and losses fell by 66.82% to ¥13,922,308.47[6] - Basic and diluted earnings per share were both ¥0.11, down 64.52% compared to the same period last year[6] - Total operating revenue for Q1 2024 reached ¥504,874,103.59, a 20.7% increase from ¥418,365,040.62 in Q1 2023[27] - Net profit for Q1 2024 was ¥16,536,169.84, a decrease of 64.1% compared to ¥46,068,348.53 in Q1 2023[28] - The total comprehensive income for Q1 2024 was CNY 16,883,201.98, compared to CNY 46,325,683.35 in the same period last year, indicating a substantial drop[29] - The basic and diluted earnings per share for Q1 2024 were both CNY 0.11, down from CNY 0.31 in Q1 2023, showing a decrease of approximately 64.52%[29] Assets and Liabilities - Total assets increased by 3.08% to ¥4,321,442,734.99 compared to the end of the previous year[6] - Cash and cash equivalents decreased to ¥445,315,659.88 from ¥483,611,131.37 in the previous quarter[23] - Total assets increased to ¥4,321,442,734.99 from ¥4,192,207,930.25 in the previous quarter, representing a growth of 3.1%[24] - Total liabilities rose to ¥1,758,122,155.73 from ¥1,665,929,876.55 in the previous quarter, indicating an increase of 5.5%[25] - The company's inventory stood at ¥1,159,862,781.66, slightly up from ¥1,145,471,760.05 in the previous quarter[23] - Long-term equity investments decreased to ¥60,950,420.41 from ¥63,531,275.19 in the previous quarter, a decline of 4.1%[23] Cash Flow - The company reported a net cash flow from operating activities of ¥28,325,486.01, which is not applicable for year-on-year comparison[6] - Cash inflows from operating activities totaled CNY 474,799,584.50 in Q1 2024, an increase of 26.96% from CNY 373,898,358.75 in Q1 2023[31] - The net cash flow from operating activities improved to CNY 28,325,486.01 in Q1 2024, compared to a net outflow of CNY -147,839,554.95 in Q1 2023[31] - The company experienced a net cash outflow from investing activities of CNY -119,512,265.14 in Q1 2024, a slight improvement from CNY -165,815,091.20 in Q1 2023[32] - Cash and cash equivalents at the end of Q1 2024 stood at CNY 443,831,829.96, up from CNY 300,142,110.84 at the end of Q1 2023[32] - The company reported a significant increase in cash received from sales of goods and services, amounting to CNY 459,234,993.50 in Q1 2024, compared to CNY 366,230,295.47 in Q1 2023, marking a growth of 25.41%[31] - The company’s total cash outflow from operating activities was CNY 446,474,098.49 in Q1 2024, down from CNY 521,737,913.70 in Q1 2023, indicating improved cash management[31] Research and Development - Research and development expenses totaled ¥53,593,858.98, accounting for 10.62% of operating revenue, a decrease of 1.46 percentage points year-on-year[6] - Research and development expenses for Q1 2024 amounted to ¥53,593,858.98, compared to ¥50,524,023.51 in Q1 2023, reflecting a 4.1% increase[28] Shareholder Information - The company completed the employee stock ownership plan by purchasing a total of 4,066,437 shares, representing 2.70% of the current total share capital, at an average price of 36.88 RMB per share, totaling 149.9754 million RMB[19] - The employee stock ownership plan was approved on February 19, 2024, allowing for a maximum of 449,640 shares, which is 2.99% of the total share capital, with participation limited to 60 employees[18] - The company reported that the top 10 shareholders include significant entities such as Junxin (Shanghai) Equity Investment Fund Management Co., Ltd. holding 10,744,524 shares, and Hong Kong Central Clearing Limited holding 6,239,974 shares[15] - The total number of shares held by the top 10 unrestricted shareholders is significant, with the largest shareholder holding over 10 million shares[15] - The company’s stock purchase for the employee stock ownership plan was executed through the secondary market, including block trades and centralized bidding[18] - The company’s stock will be locked for 12 months from March 22, 2024, to March 21, 2025, as part of the employee stock ownership plan[19] - The company’s financial report includes a detailed list of major shareholders and their respective holdings, emphasizing the concentration of ownership among a few key investors[15] Operational Insights - The decline in net profit was attributed to a slowdown in investment in the pharmaceutical industry, increased competition, and higher operational costs due to the initial production phase of the Anshan factory[10] - The company has strengthened its sales team, resulting in increased sales expenses compared to the same period last year[10] - Non-recurring gains and losses amounted to ¥2,835,042.99 after tax and minority interest adjustments[10] - The company has not reported any changes in the number of shares lent or returned through the securities lending program compared to the previous period[17] - The company has not disclosed any significant operational changes or new strategies in the current report[18] - Total operating costs for Q1 2024 were ¥465,236,626.83, up 31.2% from ¥354,607,032.39 in Q1 2023[27]

2024年04月25日 医药 | --- | --- | --- | --- | --- | --- | |---------------------|-------|-------|-------|-------|-------| | | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业收入 ( 百万元 ) | 1,358 | 1,880 | 2,357 | 2,962 | 3,776 | | YOY(%) | 40.1 | 38.4 | 25.3 | 25.7 | 27.5 | | 净利润 ( 百万元 ) | 194 | 127 | 140 | 213 | 315 | | YOY(%) | 1.4 | -34.2 | 10.1 | 51.7 | 47.8 | | 毛利率 (%) | 51.4 | 45.2 | 42.6 | 43.4 | 44.4 | | 净利率 (%) | 14.3 | 6.8 | 6.0 | 7.2 | 8.3 | | ROE(%) | 8.3 | 5.1 | 5.3 | 7.4 | 9.9 | | EPS( 摊薄 / 元 ) | 1.29 | ...

关于 2023 年度会计师事务所的履职情况评估报告 上海皓元医药股份有限公司（以下简称"公司"）聘请容诚会计师事务所 （特殊普通合伙）（以下简称"容诚会计师事务所"）作为公司 2023 年度财务报 告审计机构。根据《中华人民共和国公司法》《中华人民共和国证券法》和《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规范 性文件的规定，以及公司《董事会审计委员会实施细则》的有关规定，现将公 司关于 2023 年度会计师事务所的履职情况评估报告汇报如下： 上海皓元医药股份有限公司 一、会计师事务所的基本情况 1.基本信息 2.人员信息 截至 2023 年 12 月 31 日，容诚会计师事务所共有合伙人 179 人，共有注册 会计师 1395 人，其中 745 人签署过证券服务业务审计报告。 3.业务规模 容诚会计师事务所经审计的 2022 年度收入总额为 266,287.74 万元，其中审 计业务收入 254,019.07 万元，证券期货业务收入 135,168.13 万元。 容诚会计师事务所共承担 366 家上市公司 2022 年年报审计业务，审计收费 总额 42,888.06 万元，客户 ...

内部控制审计报告 上海皓元医药股份有限公司 容诚审字[2024]200Z0321 号 容诚会计师事务所(特殊普通合伙) 中国·北京 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是皓元 医药董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制审计报告 容诚会计师事务所(特殊普通合伙) 总所：北京市西城区阜成门外大街 22 号 外经贸大厦 15 层/922-926(10037) TEL: 010-6600 1391 FAX: 010-6600 1392 E-mail:bj@rsmchina.com.cn https//WWW.rsm.global/china/ 容诚审字[2024]200Z0321 号 上海皓元医药股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了上海皓元医药股份有限公司（以下简称"皓元医 ...

上海皓元医药股份有限公司 董事会审计委员会对 2023 年度会计师事务所 履行监督职责情况报告 上海皓元医药股份有限公司（以下简称"公司"）聘请容诚会计师事务所 （特殊普通合伙）（以下简称"容诚会计师事务所"）作为公司 2023 年度财务 报告审计机构。根据《中华人民共和国公司法》《中华人民共和国证券法》《国 有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所科创板股票上 市规则》和《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等相关规范性文件的规定，以及公司《董事会审计委员会实施细则》的有 关规定，现将公司董事会审计委员会对 2023 年度会计师事务所履行监督职责情 况报告汇报如下： 一、2023 年年审会计师事务所基本情况 1.基本信息 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普 通合伙）更名而来，初始成立于 1988 年 8 月，2013 年 12 月 10 日改制为特殊普 通合伙企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从 事证券服务业务。注册地址为北京市西城区阜成门外大街 22 号 1 幢外经贸大厦 901-22 至 901-26 ...

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 127,449,113.65, with the parent company reporting a net loss of RMB 61,257,435.24[15]. - The proposed cash dividend is RMB 1.50 per 10 shares, totaling RMB 22,558,100.85, which represents 17.70% of the annual net profit attributable to shareholders[15]. - The company reported a significant increase in revenue, achieving a total of $X million for the fiscal year, representing a Y% growth compared to the previous year[24]. - The company's revenue for 2023 reached ¥1,880,046,769.14, representing a 38.44% increase compared to ¥1,358,053,975.22 in 2022[36]. - The net profit attributable to shareholders decreased by 34.18% to ¥127,449,113.65 from ¥193,643,498.25 in the previous year[36]. - The net profit excluding non-recurring gains and losses was ¥110,127,096.45, down 29.58% from ¥156,383,214.80 in 2022[36]. - The company's basic and diluted earnings per share for 2023 were both CNY 0.85, representing a decrease of 36.09% compared to CNY 1.33 in 2022[38]. - The overall financial performance indicates a strong revenue growth trajectory despite challenges in net profit margins[36]. Operational Highlights - The company has over 11,000 global partners and operates more than 10 R&D and production bases[6]. - The workforce includes over 3,300 employees, with more than 2,000 being technical personnel[6]. - The company has outlined various risks and countermeasures in its management discussion and analysis section[13]. - The company has established multiple R&D centers, including the Anhui Haoyuan Biopharmaceutical R&D Center and the Shanghai Innovative Drug CDMO R&D Center, which have completed over 220 projects and conducted more than 280,000 tests[60]. - The company has established a stable production scaling process for over 100 types of chiral molecular building blocks, achieving laboratory-scale production[162]. Research and Development - The company is investing in R&D, allocating I% of its revenue towards the development of new technologies and drug formulations[24]. - Research and development expenses accounted for 11.92% of operating revenue, down 2.92 percentage points from 14.84% in 2022[38]. - The company has developed a robust pipeline of high-activity recombinant proteins through optimized expression and purification technologies[174]. - The company is focusing on the development of new drug types, including antibody-drug conjugates and small molecule-drug conjugates[36]. - The company is actively exploring AI applications in drug discovery to accelerate compound discovery and enhance R&D efficiency, establishing strategic partnerships with other biotech firms[113]. Market Strategy - The company is expanding its market presence in E regions, targeting a market share increase of F% by the end of the next fiscal year[24]. - The company plans to enhance market expansion efforts despite the competitive landscape and declining prices in certain product lines[39]. - The company has established a global sales network and has formed stable partnerships with multinational pharmaceutical giants and renowned research institutions, enhancing its market presence[179]. - The company is expanding its CDMO capabilities to support the commercialization of new drugs, aiming to accelerate the time-to-market for innovative therapies[176]. - The company is focused on optimizing processes and establishing quality standards for its products, ensuring compliance with regulatory requirements[156]. Challenges and Risks - The company has not yet achieved profitability since its listing[13]. - The net profit attributable to shareholders decreased by 34.18% due to intensified industry competition, declining order prices, and increased financial expenses from short-term borrowings[39]. - The company faced challenges in the pharmaceutical industry, including a slowdown in investment and financing, leading to a significant change in market demand[39]. - The company is exposed to risks from intensified domestic and international market competition, with an increasing number of competitors[188]. - The company faces risks related to technology innovation and new product development, which could impact its market competitiveness if not managed effectively[185]. Product Development - New product development includes the launch of C innovative drugs, which are expected to contribute D% to total revenue in the upcoming year[25]. - The company has developed over 28,000 proprietary products and has a cumulative reserve of over 116,000 molecular building blocks and tool compounds, including approximately 80,000 molecular building blocks and 36,000 tool compounds[81]. - The company has synthesized over 2,000 compounds with anti-tumor activity, optimizing synthetic routes and processes for these compounds[157]. - The company has developed a comprehensive platform for antibody-drug conjugates (ADCs), completing dozens of ADC antibody coupling processes and characterization methods[21]. - The company is focusing on the development of complex specialty APIs, which have high entry barriers due to their intricate synthesis processes[112]. Sustainability and Compliance - The company emphasizes sustainable development and has implemented ESG management strategies[10]. - The company has established a comprehensive quality management system, achieving certifications such as ISO 9001:2015 and ISO 14001:2015, ensuring high efficiency and accuracy in operations[183]. - The company has established a sustainable supply chain management system to minimize supply chain-related risks, ensuring high-quality procurement to meet customer demands[87]. - The company has implemented a comprehensive cGMP system at its industrial bases, ensuring compliance with international standards and enhancing operational efficiency[64]. - The company has established a polymer research and analysis center, aiming to lead in the domestic market for medical and pharmaceutical applications[155].

CONTENTS 目 录 HAOYUAN CHEMEXPRESS ESG 管理策略 | ESG 理念 | 15 | | --- | --- | | ESG 管治架构 | 16 | | 利益相关方沟通 | 17 | | 实质性议题分析 | 19 | 赋能客户，提出"皓元方案" | 创新赋能企业增长 | 35 | | --- | --- | | 打造优质客户服务 | 37 | | 严格把控产品质量 | 41 | | 构建可持续供应链 | 45 | | 创新驱动，卓越服务——打造覆盖药物发 | | | 现到产业化全周期的一体化服务平台 | 48 | | 担当履责，展现"皓元力量" | | | --- | --- | | 锻造行业领军英才 | 53 | | 多元、平等与包容 | 59 | | 职业、健康与安全 | 62 | | 实践长效公益机制 | 65 | | 协同发展服务全球 | 67 | 前言 | 关于本报告 | 01 | | --- | --- | | 董事长致辞 | 03 | | 2023 年度 ESG 亮点绩效 | 05 | | 公司概述 | 07 | | 责任运营，凝聚"皓元智慧" | | | --- ...

上海皓元医药股份有限公司 董事会关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法 律法规以及 《 上海皓元医药股份有限 公司章程》（以下简称 " 《公司章 程》"）、《上海皓元股份有限公司独立董事工作制度》等要求，并结合独 立董事出具的《独立董事独立性自查情况表》，上海皓元医药股份有限公司 （以下简称"公司"）董事会就公司在任独立董事高垚、袁彬、张兴贤在任 的独立性情况进行评估并出具如下专项意见： 经核查，独立董事高垚、袁彬、张兴贤及其直系亲属和主要社会关系人 员的任职经历以及独立董事签署的相关自查文件，独立董事高垚、袁彬、张 兴贤不存在《上市公司独立董事管理办法》第六条不得担任独立董事的情形， 在担任公司独立董事期间，独立董事已严格遵守中国证监会和上海证券交易 所的相关规定，确保有足够的时间和精力勤勉尽责地履行职责，作出独立判 断，不受公司主要股东、实际控制人或其他与公司存在利害关系的单位或个 人的影响。公司独立董事高垚、袁彬、张兴贤符合《上市公司独立董事管理 办法》《上海证券交易所 ...

证券代码：688131 证券简称：皓元医药 公告编号：2024-037 上海皓元医药股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2024 年 5 月 21 日（星期二）13:00-14:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 2 、 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/ 3、会议召开方式：上证路演中心视频直播和网络互动 三、参会人员： 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2024 年 5 月 14 日（星期二）至 5 月 20 日（星期一）16:00 前登 录上证路演中心网站首页点击 " 提问预征集 " 栏目或通过公司邮箱 hy@chemexp ...

证券代码：688131 证券简称：皓元医药 公告编号：2024-028 上海皓元医药股份有限公司 关于公司计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海皓元医药股份有限公司（以下简称"公司"）2023 年度计提存货跌价准 备 8,245.82 万元，影响 2023 年度利润总额 8,245.82 万元，减少归属于母公 司所有者的净利润 7,165.59 万元，占 2023 年度经审计归属于母公司净利润 的 56.22%。 公司于 2024 年 4 月 23 日召开第三届董事会第三十五次会议以及第三届监 事会第三十三次会议，审议通过了《关于公司计提资产减值准备的议案》，现将 相关情况公告如下： 一、本次计提资产减值准备情况概述 为客观反映公司财务状况和资产价值，根据《企业会计准则》及公司会计政 策等相关规定，公司及子公司对截至 2023 年 12 月 31 日的资产进行了减值测试， 基于谨慎性原则，公司 2023 年度计提各项资产减值准备合计 9,623.13 万元，具 体情况如 ...